Background-Early detection of haematogenous dissemination of epithelial tumours afforded by the analysis of epithelial antigen expression in the peripheral blood mononuclear fraction (PBMN) and bone marrow may confer a worse prognosis to patients with carcinoma. Cytokeratin 19 is a protein normally expressed by epithelial cells including normal and malignant mammary cells. Previous studies have demonstrated that analysis of cytokeratin 19 expression by the reverse transcriptasepolymerase chain reaction (RT-PCR) can detect one epithelial cell in as many as IO-IO' haematopoetic cells. Despite its sensitivity concern has been voiced recently about the specificity of this technique owing to the detection of cytokeratin 19 expression in the PBMN of normal volunteers and the bone marrow of patients with haematological malignancies. Aims-To assess the sensitivity and specificity of RT-PCR detection of cytokeratin 19 in PBMN of normal female blood donors. Methods-Blood was taken from 52 normal female blood donors and PBMN separated through Fycol gradient centrifugation. Cytokeratin 19 was measured using a two step nested RT-PCR assay. Results-No amplification was found in the first step for any of the samples studied, whereas in the second step amplification was observed in 10 of the 52 samples. Both steps could detect one MCF-7 cell (the cytokeratin 19 positive control) in 106 CEM (cytokeratin 19 negative control) cells.
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Another explanation for the observed nonspecificity could be the incorporation of a second step into the PCR technique. In fact, when we studied both steps in terms of their sensitivity in dilutional assays, we found that both of them could detect one MCF-7 cell in 1 o6 CEM cells. However, the second step was positive in -36% of normal controls, whereas the first step of the technique did not detect cytokeratin 19 transcripts in any of the controls studied. In the papers by Data et al6 and Krismann et al9 it was impossible to tell at which step amplification of cytokeratin 19 transcripts occurred, either in the positive patients or in the false positive controls. It is possible, therefore, that the potential increase in sensitivity provided by a second PCR step may occur at the expense of a lower specificity of the whole assay. In our study, the first step of this technique achieved a degree of sensitivity similar to that described in the literature, with 100% specificity, therefore, the need for a second step may have to be re-evaluated.
Our results were based on a breast cancer cell line (MCF-7) and PBMN cells from normal adult female blood donors. Therefore, in order to extrapolate these results to other types of tumour and patients, further studies need to be carried out using different tumour cell lines and other normal control cell populations. Furthermore, additional studies are needed to confirm our findings and to assess the value of the first step of this technique for the detection of cytokeratin 19 transcripts in the blood and bone marrow of patients with breast cancer. 
